A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID - Nature Communications
www.nature.com
A novel antiviral targeting the SARS-CoV-2 PLpro protease shows strong efficacy in a mouse model, preventing lung pathology and reducing brain dysfunction. The study provides proof-of-principle that PLpro inhibition may be a viable strategy for preventing and treating long COVID.
This is an automated archive made by the Lemmit Bot.

The original was posted on /r/science by /u/fugapku on 2025-04-12 01:49:34+00:00.

Original Title: A new study in Nature Communications reports a novel PLpro inhibitor that improves outcomes in a preclinical model of long COVID. This compound shows promise in reducing lung pathology and brain dysfunction, offering potential for future treatments.